InspireMD raises $58M via PIPE and warrant exercise; appoints Ray Cohen to board

InspireMD, Inc.

PIPE gross proceeds $40.1M: 16.6M shares/pre-funded warrants at $2.42/share; led by OrbiMed and Marshall Wace.
Warrant exercise yields $17.9M: 12.9M Series I warrants exercised at $1.3827, triggered by FDA PMA of CGuard Prime.
Combined $58M to fund U.S. commercial launch of CGuard Prime; intended use includes sales/marketing, R&D, working capital.
Raymond W. Cohen appointed to Board (Cl. 3), effective Aug 1; former CEO of Axonics (sold to BSX for $3.7B), brings MedTech scaling expertise.
Directors Kathryn Arnold and Thomas Kester will not stand for reelection in 2026; expected resignations by Dec 31, 2025.

item 1.01item 3.02item 5.02item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.